Dynavax raised to market outperform by JMP

Dynavax Technologies Corp. was upgraded to market outperform from market perform with an $8 price target by JMP Securities analyst Charles C. Duncan. Dynavax announced a strategic financing deal with Symphony Capital Partners that the analyst believes will accelerate the company's pipeline. Shares of the Berkeley, Calif., pharmaceutical company were up 61 cents, or 12.35%, at $5.55 on volume of 332,604 shares versus the three-month running average of 96,147 shares. (Nasdaq: DVAX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.